Alcon: Cataract Surgery with AcrySof IQ Vivity IOLs Demonstrates Sustained High Patient Satisfaction and Reduced Spectacle Dependence
Alcon revealed final data from its Vivity Registry Study, which monitored real-world patient experiences for up to 12 months post-cataract surgery with implantation of either AcrySof IQ Vivity or AcrySof IQ Vivity Toric presbyopia-correcting intraocular lens (PCIOL). Data from more than 900 cataract patients demonstrated sustained clinical performance, high patient satisfaction, and reduced dependence upon spectacles (glasses). Evidence also suggested that AcrySof IQ Vivity can be used successfully in a broad range of patients, providing surgeons and patients with additional treatment options, according to Alcon.
“Since its introduction, AcrySof IQ Vivity has been a disruptive technology—and an innovation we are very proud of as a company. Vivity is a first-of-its kind, non-diffractive extended depth of focus IOL built with our proprietary X-WAVE technology, which stretches and shifts light without splitting it,” Sunil Vasanth, VP, Europe Surgical Franchise, Alcon, said in a company news release. “Our real-world registry data gives surgeons the confidence that Vivity’s performance is sustained over time. This data is also important as it includes patients with common mild comorbidities like glaucoma, dry eye and retinopathy/maculopathy.”
The Vivity Registry Study[3] was a multicenter, ambispective, non-comparative, open-label, non- interventional registry study conducted across 41 sites from eight (8) countries: Australia, Belgium, Germany, New Zealand, the Netherlands, Portugal, Spain and the United Kingdom. Researchers concluded that:
Three-quarters of patients reported no difficulty with their sight for activities in everyday life
Most patients (92%) reported they were satisfied with their sight
More than 91% of patients reported no halos, glares or starbursts† (common visual disturbances that come from splitting the light in a diffractive IOL)
Excellent binocular distance and intermediate uncorrected visual acuity was observed, with mean Snellen visual acuity values of 20/20 and 20/25, respectively
More than 78% and 88% of patients reported they no longer needed to use glasses to see at arm’s length and far away, respectively
These results and additional data are being discussed in 11 sessions with world-renowned surgeons at the 41st Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), currently underway in Vienna, Austria. For a full overview of relevant abstracts, visit MyAlconatESCRS.com.
AcrySof IQ Vivity, a non-diffractive IOL, uses Alcon’s proprietary Wavefront-Shaping X-WAVE technology, a next-generation optical principle that stretches and shifts light without splitting it.[2] As a result, it fulfils an unmet medical need to provide excellent distance, intermediate and functional near vision (e.g., for close-up daily activities such as using a mobile device), while maintaining low visual disturbances.[2]
References
AcrySof® IQ Vivity® Extended Vision IOL DFU.
Bala et al. Multicountry clinical outcomes of a new nondiffractive presbyopia-correcting IOL. J Cataract Refract Surg. 2022; 48:136–143.
Reus NJ, Kooijman M, Perez-Vives C. Overall Visual Outcomes from a Real-world Study of Presbyopia-correcting IOLs in a Large Population. Presented at the European Society of Cataract and Refractive Surgery (ESCRS) Annual Meeting; 8-12 Sept, 2023; Vienna, Austria.
Alcon Cataract Survey [REF-21516].